Viking Therapeutics

Drug Discovery · Oncology Therapeutics
11Open roles6 posted in 30 days
$210kMedian advertised pay9 postings state pay
Data updated Nov 22, 2026Full reportReport a mistake
Lately:8 news stories in 90 daysFollow changes →

Facts

as of Nov 22, 2026

Improving life and health through next-generation science Novel Therapies for Metabolic and Endocrine Disorders. Viking Therapeutics is a clinical-stage biotechnology company advancing a next-generation portfolio of therapies for obesity and metabolic disease.

It is hiring: 11 open roles, 6 of them posted in the last 30 days.

Headquarters
San Diego, United States
Founded
2012
Employees
53US Form 5500 (plan participants) · Dec 2025 · +47% in a year
Legal entities
2 in 2 countries
Listing
NASDAQ: VKTX
Open roles
11 in 2 citiesAlion job postings

As of Nov 22, 2026, Alion lists 11 open roles at Viking Therapeutics. Viking Therapeutics is headquartered in San Diego, United States. It was founded in 2012. The median pay stated in its open roles is $210k, across 9 postings that state pay.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Viking Therapeutics operates through 2 legal entities in 2 countries.

Legal entities2 in 2 countries
operator · US EIN 461073877 · LEI 529900IVC72YPFA25M37
US
subsidiary · IE CRO 779389
IE
Holders and shares as each register or filing states them.

11 open roles, 6 of them posted in the last 30 days.

11Open roles6 posted in 30 days
$210kMedian advertised pay$150k – $215k
53EmployeesUS Form 5500 (plan participants) · Dec 2025 · +47% in a year
Head countas filed and stated
Where the openings areshare of open roles
Biotech50%▼
Engineering30%▲
Communications10%▼
Management10%▲
Open roles over time−100%
Sep 28This week
Open roles a week: 5 then, 0 now
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family

Products

Products →

Viking Therapeutics has 13 clinical trials on record, 6 under way.

#953,597Web rankTranco top 1M
Clinical trials
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
phase 3 · under way · 560 participants · Weight Loss
Nov 2026
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
phase 3 · under way · 560 participants · Weight Loss
Nov 2026
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
phase 1 · under way · 56 participants · Obese Adults
Jul 2026
Tech stack21
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

Viking Therapeutics: 1 notable 8-K reports, 1 federal court cases.

Legal entity active
Viking Therapeutics, Inc.
Yes
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Court cases
Dec 2022 – Dec 2022 · 0 as defendant · 0 closed
1
Patents
1
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Went public NASDAQ: VKTX
Nov 2026
Team of 53 was 36 · US Form 5500 (plan participants)
2025
Founded per the company register
Sep 24, 2012
Sources: the outlets named on each headline, each story once

Ranked #1 by open roles among its 11 closest peers.

#CompanyHQOpen rolesSize
1Viking TherapeuticsSan Diego, United States11201-500
2Cognito Therapeutics, Inc.Cambridge, United States1151-200
3Remix TherapeuticsWatertown, United States8
4KriyatxPalo Alto, United States8201-500
4 more records: closest peers with their size and open rolesProUnlockor this company alone for 30 days · 50 credits
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)